InsiderSignal.AI

InsiderSignal.ai

TLSI - Trisalus Life Sciences, Inc.

Insider Sale by Szela Mary T (CEO, Pres)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Szela Mary T, serving as CEO, Pres at Trisalus Life Sciences, Inc. (TLSI), sold 20,302 shares at $3.91 per share, for a total transaction value of $79,383.00. Following this transaction, Szela Mary T now holds 752,987 shares of TLSI.

This sale represents a 3.00% decrease in Szela Mary T's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, March 11, 2026 and publicly disclosed via SEC Form 4 filing on Friday, March 20, 2026, 9 days after the trade was made.

Trisalus Life Sciences, Inc. operates in the HEALTHCARE sector, specifically within the MEDICAL DEVICES industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Szela Mary T

Szela Mary T

CEO, Pres

Mary T. Szela is the President, Chief Executive Officer, and Director of TriSalus Life Sciences, Inc. (TLSI), a position she has held since January 2018. With nearly 35 years of experience in the biopharmaceutical industry, she has driven growth in commercial and clinical sectors, including leading TriSalus in oncology-focused innovations for liver and pancreatic tumors using novel delivery technology.[[1]](https://www.marketscreener.com/insider/MARY-SZELA-A0813O/)[[2]](https://trisaluslifesci.com/snr-management/mary-szela/)[[5]](https://www.smartbusinessdealmakers.com/denver/event-2024/speakers/mary-szela/) Prior to TriSalus, Szela served as CEO of Novelion Therapeutics (2016-2017), where she managed regulatory challenges and orchestrated a merger of Aegerion Pharmaceuticals and QLT Therapeutics, and as CEO of Melinta Therapeutics (2013-2015), accelerating development of MRSA treatments. She held senior roles at Abbott Laboratories, including President of its $8 billion U.S. pharmaceuticals business and SVP of Global Strategic Marketing & Services (2010-2012), contributing to global brands like Humira. Szela currently serves on boards including Kura Oncology (since 2018), Absci Corp. (since 2025), and others, with past roles at Prometheus Biosciences, Omega Therapeutics, and Coherus Oncology. She holds a B.S. in Nursing and an MBA from the University of Illinois at Chicago.[[1]](https://www.marketscreener.com/insider/MARY-SZELA-A0813O/)[[2]](https://trisaluslifesci.com/snr-management/mary-szela/)[[3]](https://kuraoncology.com/about-us/)[[4]](https://www.gurufocus.com/insider/6294/mary-t-szela)

View full insider profile →

Trade Price

$3.91

Quantity

20,302

Total Value

$79,383.00

Shares Owned

752,987

Trade Date

Wednesday, March 11, 2026

12 days ago

SEC Filing Date

Friday, March 20, 2026

Filed 9 days after trade

HEALTHCAREMEDICAL DEVICES

About Trisalus Life Sciences, Inc.

Company Overview

No company information available
View news mentioning TLSI

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4948863

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime